The biotech company InSphero, which is based in Schlieren in the canton of Zurich, has signed a partnership agreement with the Frankfurt-based company Genome Biologics. According to a statement, InSphero will receive the exclusive global rights to commercialize Genome Biologics' 3D Cardiac Organoid Platform. The platform is at the forefront of cardiac disease research and offers precise, scalable and disease-specific organoid models for the development of new therapeutics.
Biomedical research is increasingly making use of organoids. These are tiny organ-like structures, only a few millimetres in size, that are produced in the laboratory. Organoids can be used to study life processes and the effect of drugs. As they are very similar to real organs, they offer advantages over other cell cultures. Researchers can observe the heart and diseases in a new way, which enables the faster and more precise development of cardiac therapeutics.
“By combining our expertise in organoid technology with InSphero's robust commercial capabilities, we are setting a new standard in the predictive accuracy of preclinical models for cardiac diseases,” Professor Jaya Krishnan, co-founder of Genome Biologics, is quoted as saying.
Filip Henzler, CFO of InSphero, describes the partnership as a pivotal moment. “The 3D Cardiac Organoid Platform not only complements our existing product offerings but also enhances our market position in providing cutting-edge solutions for complex biological modeling out of one hand,” he says.
InSphero is a spin-off from the University of Zurich (UZH) and the Swiss Federal Institute of Technology Zurich (ETH). It is based in the Bio-Technopark Schlieren-Zürich. ce/gba
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space